Genentech, a member of the Roche Group, has announced three new partnerships aimed at improving brain health outcomes. The initiatives, which aim to assess the complexity, economic impact and patient and care partner burden of brain health conditions, will generate data designed to understand the nuanced dynamics of neurologic care. Additionally, the company, along with Roche, will present 33 data abstracts on the span of neurological conditions including multiple sclerosis, neuromyelitis optica spectrum disorder and spinal muscular atrophy, among others. The initiatives will be presented by Genentech at the 75th American Academy of Neurology Annual Meeting in Boston from April 22-27.

The company is committed to advancing understanding of brain health and neurological disorders and is the number one investor in R&D among healthcare companies. More than 20% of $14.7bn invested in Roche and Genentech’s R&D in 2022 alone was dedicated to evaluating therapeutic, diagnostic and digital technology interventions to discover and potentially address brain health disorders. As part of this commitment, the company has expanded partnerships, aiming to meet current and future needs across the spectrum of brain health, including a brain health initiative with the University of Washington, Institute for Health Metrics and Evaluation Brain Health Collaborative, and the PicnicHealth BrainPower Pan-Neuroscience Patient Experience Research, which will analyse longitudinal, real-world clinical data of people living with neurologic diseases. The company is also exploring the utilisation of telehealth for neurological conditions.

Also Read:

An in-depth analysis of the Sound Equipment market size and its anticipated industrial expansion at a CAGR of 8.5% by 2030

Levi Garraway, Genentech’s chief medical officer and head of Global Product Development, said: “We are committed to developing and delivering new medicines that address areas of highest need in neuroscience. Accordingly, we have more than a dozen investigational medicines that span a range of neurological conditions, with the ultimate goal of slowing progression and delaying disability for as long as possible.” Brain and nervous system conditions cause more death and illness globally than cardiovascular disease, cancers and all other conditions.1

In Other News Around the World:

An in-depth analysis of the Sound Equipment market size and its anticipated industrial expansion at a CAGR of 8.5% by 2030

By Rachel Chen

Rachel Chen is an investigative journalist with a passion for uncovering corruption and wrongdoing. Her fearless reporting has led to several high-profile exposés and has earned her numerous awards and accolades.

Leave a Reply

Your email address will not be published. Required fields are marked *